
Faculty, Staff and Student Publications
Publication Date
4-12-2023
Journal
The Journal of Infectious Diseases
Abstract
Influenza-associated pulmonary aspergillosis (IAPA) is a feared complication in patients with influenza tracheobronchitis, especially those receiving corticosteroids. Herein, we established a novel IAPA mouse model with low-inoculum Aspergillus infection and compared outcomes in mice with and without cortisone acetate (CA) immunosuppression. CA was an independent predictor of increased morbidity/mortality in mice with IAPA. Early antifungal treatment with liposomal amphotericin B was pivotal to improve IAPA outcomes in CA-immunosuppressed mice, even after prior antiviral therapy with oseltamivir. In summary, our model recapitulates key clinical features of IAPA and provides a robust preclinical platform to study the pathogenesis and treatment of IAPA.
Keywords
pneumonia, amphotericin B, aspergillosis, corticosteroids, influenza, mouse model, oseltamivir
DOI
10.1093/infdis/jiad001
PMID
36611269
PMCID
PMC10319956
PubMedCentral® Posted Date
January 2023
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Infectious Disease Commons, Medical Sciences Commons, Pulmonology Commons
Comments
Supplementary Material
PMID: 36611269